Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
← catalyst calendarNCT07766421 · readout ≤ 1,991 d
Sponsored by Cellectar Biosciences, Inc. (industry) · CLRB — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
219estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2026 | estimated | When the study began enrolling |
| Primary completion | Jan 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Waldenstrom Macroglobulinaemia
- Waldenstrom Macroglobulinemia
- Waldenstrom's Macroglobulinaemia Refractory
- Waldenstrom Macroglobulinemia With Nodal Disease
- Waldenstrom's Macroglobulinemia Recurrent
Interventions
- Drug: Iopofosine I 131 — also filed as CLR 131
- Drug: Rituximab (active comparator)
- Drug: Cyclophosphamate
- Drug: Dexamethasone
Primary outcome
what the primary-completion date above is the date OFSuperiority of progression free survival (PFS)
measured From baseline randomization through study completion of progressive disease, or death due to any reason (whichever status is recorded first).
Permalink · CLRB's whole pipeline · Catalyst calendar · Every registered study · What changed